仙琚製藥(002332.SZ):舒更葡糖鈉注射液新納入國家醫保目錄
格隆匯1月19日丨仙琚製藥(002332.SZ)公佈,2023年1月18日,國家醫保局、人力資源社會保障部發布了《關於印發<國家基本醫療保險、工傷保險和生育保險藥品目錄(2022年)>的通知》(醫保發〔2023〕5號),公佈了《國家基本醫療保險、工傷保險和生育保險藥品目錄(2022年)》(簡稱《國家醫保目錄》(2022年版)),該目錄自2023年3月1日起正式實施。
公司共有34個品種(64個品規)納入《國家醫保目錄》(2022年版),其中甲類12個品種(19個品規),乙類22個品種(45個品規)。公司的主要產品糠酸莫米松鼻噴霧劑、噻託溴銨吸入粉霧劑、糠酸莫米松乳膏、黃體酮膠囊、米索前列醇片、羅庫溴銨注射液、注射用苯磺順阿曲庫銨、醋酸地塞米松片、地塞米松磷酸鈉注射液、甲潑尼龍片等繼續納入《國家醫保目錄》(2022年版)。
舒更葡糖鈉注射液為此次新納入《國家醫保目錄》(2022年版)。舒更葡糖鈉注射液製劑中的活性成分舒更葡糖是一種經修飾的γ-環糊精,可以選擇性結合神經肌肉形成複合物,阻斷神經肌肉阻滯藥物羅庫溴銨或維庫溴銨,進而降低在神經肌肉2接頭處與煙鹼受體相結合的神經肌肉阻滯藥物的數量,由此拮抗由羅庫溴銨或維庫溴銨誘導的神經肌肉阻滯。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.